Log in to save to my catalogue

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a...

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_436353bf6b554a7ca56ec210185c93df

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial

About this item

Full title

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-01, Vol.15 (1), p.493-493, Article 493

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA), was administered in recurrent GBM patients either at the resection cavit...

Alternative Titles

Full title

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_436353bf6b554a7ca56ec210185c93df

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_436353bf6b554a7ca56ec210185c93df

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-43076-7

How to access this item